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ABSTRACT
Background. Whether the TNM staging system is appli-
cable after neoadjuvant chemoradiation in esophageal
cancer is controversial. The aim of this study was to
evaluate the prognostic value of histopathological regres-
sion of the primary tumor in postchemoradiated patients.
Materials and Methods. The pretherapeutic and patho-
logical ypTNM stages of patients who have had
neoadjuvant chemoradiation followed by esophagectomy
were analyzed. The percentage of residual viable cells of
the primary tumor (ypV) and other clinicopathological
factors were tested for their prognostic value.
Results. Of 175 recruited patients, 55 (31.4%) achieved
pathological complete response. The median survival of
these 55 patients was significantly longer than those with
other disease stages (124.8 vs 21.1 months) (P \ .001).
Gender, ypT, ypN, ypTNM, and ypV stage were significant
prognostic factors in univariate analysis. In patients with-
out nodal metastases, the median survival in patients with
residual viable cells in the primary tumor (ypV?) was
24.6 months, compared with that of 124.8 months in those
with no viable cells (ypV0) (P = .043). In those who had
nodal metastases, the median survival of patients with
ypV0 and ypV? were 21.2 months and 17.4 months
respectively (P = .37). Cox regression analysis showed
that male gender, high percentage of residual viable cells
(ypV), and positive nodal status (ypN1) were independent
predictors of poor prognosis.
Conclusions. In patients who underwent neoadjuvant
chemoradiation therapy, histopathological regression of the
primary tumor indicated by percentage of residual viable
cells is an important prognostic factor in addition to nodal
status and gender.
The American Joint Committee on Cancer (TNM)
staging system is used to stratify esophageal cancer
patients for different therapeutic strategies.1 The staging
system accurately predicts long-term survival in patients
treated with surgical resection alone.2 For locoregionally
advanced esophageal cancer however, the outcome is
generally poor after surgical resection.3,4 In order to
improve outcome, neoadjuvant chemoradiation therapy
followed by surgery is increasingly used to treat esopha-
geal cancer.5,6 In this situation, it remains unclear if the
same TNM staging system is applicable after surgery to
guide prognosis. In a previous study, we have demonstrated
that ypTNM staging after neoadjuvant chemoradiation was
suboptimal in prognostication.7,8 Similar findings have also
been reported in the literature.7,9,10 Evaluating histopa-
thological regression in the surgical specimen may be a
better way to assess prognosis.11–13
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The aims of the present study were to investigate the
prognostic value of the ypTNM staging system and assess
the significance of the percentage of viable residual cells in
the esophagus by histopathological examination in patients
who had had received neoadjuvant chemoradiation therapy.
PATIENTS AND METHODS
From 1995 to 2007, 183 patients who had squamous cell
esophageal carcinoma and who received neoadjuvant che-
moradiation followed by surgery at the Queen Mary
Hospital, The University of Hong Kong, were included in
this study. Neoadjuvant chemoradiation treatment was
given as part of a randomized controlled trial comparing
neoadjuvant chemoradiation versus surgical resection alone
or when locally advanced tumor or nonregional metastatic
nodal spread was present. In these situations, a R0 resec-
tion was judged not probable and thus chemoradiation was
used upfront. Patients with systemic organ metastases were
not selected for surgical treatment and thus were excluded.
Only patients who had R0 resections were included in this
study because patients who had incomplete tumor resection
invariably would have a poor prognosis. Tumors located at
the cardia or nonsquamous cell cancers were excluded.
For all patients, staging investigations included upper
endoscopy, endoscopic ultrasound (EUS) and bronchos-
copy, ultrasound of the neck with or without fine-needle
aspiration cytology of suspected nodes, computer tomog-
raphy (CT), or positron emission tomography fusion with
computer tomography (PET/CT) imaging (PET/CT scan
was available since 2003). Chemoradiation therapy was
given in a concurrent manner. The chemotherapy regime
comprised cisplatin at 100 mg/m2 on day 1 and then day 22
and continuous infusion of 5-fluorouracil (5-FU) at
500 mg/m2 per day for 5 days from days 1 to 5 and days 22
to 26. Radiotherapy was given at a dosage of 40–46 Gy at
2 Gy per fraction. It was delivered through anterior and
posterior opposing fields to the primary esophageal tumor
covering at least 1-cm lateral margins and 3-cm axial
margins. Postchemoradiation evaluation was performed
4 weeks after the date of finishing the treatment course, and
surgery carried out soon after.
The choice of surgical approach was governed by the
location of the tumor. For tumors located in the middle and
lower thirds of the esophagus a Lewis-Tanner esophagec-
tomy through an abdominal-right thoracotomy approach was
preferred, but three-phase esophagectomy and minimally
invasive techniques using thoracoscopic ± laparoscopic
approaches have been increasingly employed in recent years.
Two-field lymph node dissection was performed. Bilateral
cervical nodal dissection was not routine because evidence
was not strong enough to demonstrate clear benefits over
two-field lymphadenectomy but with potentially increased
morbidities.14,15
Pathological Analysis
Pathological preparation of the surgical specimen started
immediately after the operation. A surgeon identified the
lymph node groups in the specimen. They were dissected
and labeled separately from the main esophageal specimen.
Two designated pathologists (KWC, AKYL) were
responsible for the histological examination. The esopha-
gus was fixed in 10% neutral formalin overnight, serially
sectioned, and embedded into paraffin blocks. Sections
were cut at 5 lm thickness and stained with hematoxylin
and eosin for microscopic examination. The tumor zone on
the slide was labeled respectively as scar tissue, necrotic
tissue, and viable tumor. Percentage of the viable residual
tumor was then calculated by dividing the viable residual
tumor area by the total tumor area, which is the sum of the
areas categorized under the tumor zone. The percentage of
viable residual tumor was designated as a continuous var-
iable and also categorized into 4 groups as a measure of the
extent of chemoradiation response: ypV0, no viable cell;
ypV1, 1%–33% viable tumor; ypV2, 34%–66% viable
tumor; and ypV3, 67%–100% viable tumor, according to
the Guidelines of Japanese Society for Esophageal Dis-
ease.16 The deepest layer involved by malignant cells
determined the ypT-stage. The total number of harvested
lymph nodes and the location and the number of lymph
nodes with metastasis were recorded. A final pathologic
stage (ypTNM stage) was then assigned to each specimen
according to the American Joint Committee on Cancer
criteria.
Statistical Analysis
All data were collected prospectively. Categorical data
were analyzed using chi-square and Fisher exact tests
where appropriate. Continuous variables are expressed as
median (range). Survival was calculated by the Kaplan–
Meier method from the date of operation to the time of
death or last date of assessment. Log-rank test was used to
compare survival difference between groups. Prognostic
factors for survival were assessed using Cox regression for
univariate analysis and Cox proportional hazards models
were fitted for multivariate analysis (backward stepwise
[conditional LR]). Differences between groups were con-
sidered statistically significant if the P values were less
than .05. The statistical analysis was performed with SPSS
Software for Windows (SPSS, Chicago, IL).
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TABLE 1 Demographic features of patients treated with neoadjuvant chemoradiation and univariate analysis of survival in relation to clini-
copathological characteristics
Characteristics No. of patients (n = 175) (%) HR (95% CI) P value
Age, median (range) 65 (38–82) 0.994 0.974–1.015 .596
Gender .004
Male 149 (85.1) 3.1 1.422–6.761
Female (reference) 26 (14.9) 1
Level of tumor .787
Cervical (reference) 2 (1) 1
Upper 32 (18.3) 1.330 0.175–10.101 .783
Middle 104 (59.5) 1.838 0.254–13.321 .547
Lower 31 (17.7) 1.762 0.233–13.319 .583
Double 6 (3.5) 1.253 0.113–13.902 .854
Clinical stage (pretreatment)
cT stage .300
cT1 3 (1.7) 1
cT2 14 (8.0) 1.556 0.285–8.503 .610
cT3 149 (85.1) 0.500 0.133–1.876 .304
cT4 9 (5.1) 1.174 0.429–3.215 .755
cN stage .246
cN0 37 (21.1) 1
cN1 138 (78.9) 1.352 0.812–2.252
cM stage .194
cM0 146 (83.4) 1
cM1 29 (16.6) 1.432 0.833–2.460
cTNM stage .281
c-stage I (reference) 3 (1.7) 1
c-stage II 33 (18.8) 0.487 0.111–2.133 .340
c-stage III 110 (62.9) 0.727 0.177–2.983 .658
c-stage IV 29 (16.6) 0.951 0.218–4.145 .947
Pathological stage
ypT stage .006
ypT0/pTis (reference) 78 (44.6) 1
ypT1 17 (9.6) 1.844 0.947–3.588 .072
ypT2 36 (20.6) 1.485 0.841–2.624 .173
ypT3 39 (22.3) 2.626 1.543–4.467 \.001
ypT4 5 (2.9) 2.963 0.899–9.768 .074
ypN stage .001
ypN0 (reference) 111 (63.4) 1
ypN1 64 (36.6) 2.020 1.325–3.081
ypM stage .79
ypM0 (reference) 161 (92) 1
ypM1 14 (8)a 1.119 0.488–2.566
ypTNM .003
ypCR (reference) 55 (31.4) 1
ypT0N1M0 20 (11.4) 2.594 1.245–5.406 .011
y-stage I 13 (7.4) 2.579 1.188–5.601 .017
y-stage II 51 (29.2) 2.377 1.312–4.304 .004
y-stage III 22 (12.6) 4.041 2.075–7.873 \.001
y-stage IV 14 (8)a 2.254 0.892–5.695 .086
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RESULTS
Of the 183 patients who had chemoradiation followed
by surgery, 175 had total tumor clearance (R0) achieved
and were included in this study. Among these patients, 149
were men and the median age was 65 (range, 38–82). The
median follow-up was 20 months (range, 1–143). The
demographic data of these patients are shown in Table 1.
Effects, Morbidities, and Mortalities
A total of 132 (75.4%) patients had their tumor down-
staged, the tumor status of 35 patients (20.0%) remained
unchanged, and 8 patients (4.6%) had disease progression
after chemoradiation. For surgery-related morbidities, 9
patients (5.1%) had anastomotic leakage and 5 patients
(2.9%) had chylothorax. Major medical complications
including chest infection, arrhythmia, and myocardial
infarction occurred in 20 patients (11.4%). Also, 1 patient
(0.6%) died in hospital. He had a prolonged stay in hospital
after surgery because of socioeconomic reason. He even-
tually died of pneumonia with no evidence of recurrence.
Survival Analysis
At the time of data analysis, 73 patients had died; 17 of
them died from non-tumor-related cause. Overall survival
was investigated. The overall median survival of all
patients was 39.2 months. The 3-year and 5-year survival
rates were 52.8% and 40.2%, respectively. Univariate
analysis showed that the pretreatment clinical stage was not
a predictor of overall survival. The potential prognostic
factors identified were gender, pathological T stage (ypT),
pathological N stage (ypN), and the overall pathological
stage (ypTNM) (Table 1). ypV stage was tested as both a
continuous and categorical variable. For the latter, the ypV
stage was categorized into 4 groups according to the
Guidelines of Japanese Society for Esophageal Disease. In
either situation, ypV stage was a significant prognostic
factor in univariate analysis.
Male gender was a predictor of poor survival, and the
survival curve is shown in Fig. 1a. Overall, ypTNM stage-
specific survival curves are shown in Fig. 1b. No statistical
difference could be identified between each stage of dis-
ease by log-rank test. The median survival of the 55
patients (31.4%) who had pathological complete response
(ypT0N0M0) was significantly longer compared with those
with other ypTNM stages combined, at 124.8 months vs
21.1 months, P \ .00 (Fig. 1c).
Survival curves of different ypT stages from analysis of
the primary tumor status are illustrated in Fig. 2a. Advancing
ypT stages had worse prognosis. The median number of
harvested lymph nodes was 22 (range, 0–97). Among the
study group, 64 patients (36.6%) had positive malignant
lymph nodes (ypN?). The median survival of patients with
nodal metastases was 21 months compared with 65.2 months
in patients without nodal metastases (P \ .001) (Fig. 2b). Of
the 111 patients (63.4%) without nodal metastasis, 56 (32%)
had viable malignant cells identified in the primary tumor
(ypV?). The median survival of these patients was
24.6 months, which was significantly worse when compared
with the 55 patients (31.4%) who had no viable cells in the
primary tumor (ypV0), whose median survival was
124.8 months (P = .043) (Fig. 2c). In contrast, in patients
who had nodal metastases, survival of patients with ypV0
and ypV? was not significantly different; median survival
was 21.2 months and 17.4 months, respectively (P = .368)
(Fig. 2d).
Multivariate analyses using Cox proportional hazard
model for survival is shown in Table 2. ypV as a contin-
uous variable, gender, ypT, ypN and overall ypTNM stage
were entered into the model. Male gender, the percent of
TABLE 1 continued
Characteristics No. of patients (n = 175) (%) HR (95% CI) P value
Residual tumor
ypV stageb 175 (100%) 1.334 1.127–1.579 .001
ypV stagec .003
ypV0 (0%) (reference) 78 (44.6) 1
ypV1 (1–33%) 42 (24) 1.538 0.900–2.630 .116
ypV2 (34–66%) 18 (10.3) 2.065 1.013–4.209 .046
ypV3 (66–100%) 37 (21.1) 2.659 1.579–4.476 \.001
HR hazard ration, CI confidence interval
Reference against which hazard rations are calculated
a Stage IV by virtue of distant nodal metastases, distant organ metastases patients were excluded
b pV stage tested as a continuous variable
c pV stage tested as a categorical variable
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viable malignant cells in the primary tumor (ypV), and
presence of metastatic lymph node (ypN) were independent
predictors of poor prognosis. Survival of subcategories of
ypV stages is shown in Fig. 2e. A trend of separation of
survival is seen among different ypV stages. ypV as a
categorical variable, gender, and ypN were re-entered to
the Cox model for analysis. All three variables were found
to be independent poor prognostic predictors (Table 3).
DISCUSSION
In this study, we have shown that in patients who
underwent neoadjuvant chemoradiation therapy before
surgical resection, percentage of viable cells in the primary
tumor, nodal status, and gender were prognostic factors on
multivariate analysis. ypV stage could potentially replace
ypT stage. Nodal status is however even more important;
positive nodal metastasis incurs a poor prognosis even in
the presence of complete response in the primary tumor.
The beneficial effects of neoadjuvant chemoradiation
therapy, although gaining popularity, have not been con-
sistently shown in randomized trials.3,4,17–21 However,
patients who have pathological complete response
(ypT0N0M0) after neoadjuvant chemoradiation therapy
have repeatedly been shown to have better survival com-
pared with those with incomplete response.22–25 In our
group of patients, chemoradiation had substantial effects;
75.4% of patients were downstaged, and 31.4% achieved
complete response. Consistent with other reports, the long-
term survival of the complete responders was significantly
longer than those patients with residual tumor.4,19,26 The 3-
year and 5-year survival rates in ypCR patients were 72.1%
and 61.6%, respectively.
Pretherapeutic clinical TNM stage had no impact on
survival. This is not unexpected since long-term prognosis
would depend on the response to neoadjuvant treatment.
This is also consistent with the findings from other similar
studies.8,27 It is however controversial whether postsurgical
ypTNM stage is of prognostic significance or not. The
relevance of ypTNM has been variably reported by dif-
ferent investigators.10 Swisher and associates identified
ypTNM as an independent prognostic factor on multivari-
ate analysis, while data from the Memorial Sloan Kettering
Center did not find it of value.9 Our data could not dem-
onstrate the significance of ypTNM stage on multivariate
analysis. ypT stage was not prognostic on multivariate
analysis, only ypN was useful. The reason that ypTNM
stage was not prognostic may be related to an altered
relationship between ypT and ypN stage. In our previous
study, we have shown that while in patients who had sur-
 n Median 5-year
Male 149 34.8m 36.8%
Female 26 81.9m 60.4%
 n Median 5-year
ypCR 55 124.8m 61.6%
Others 120 21.1 m 30.4%
 n Median 5-year
ypCR 55 124.8 m 61.6%
yT0N1M0 20 21 m 27.2%
y-I 13 46.5 m 38.5%
y-II 51 23.4 m 41.3%
y-III 22 18.1 m 7%
y-IV 14 39.2 m 39%
1.0
0.8
0.6
0.4
0.2
1600 140
Months
100 12060 804020
Survival
a
b
p = 0.0028
1.0
0.8
0.6
0.4
0.2
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c
p < 0.01
1.0
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0.4
0.2
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p = 0.003
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100 12060 804020
1600 140
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100 12060 804020
FIG. 1 a Survival curve with gender as a predictor of survival. b
Survival curve of overall ypTNM stage for patients treated with
neoadjuvant chemoradiation followed by surgery. c Survival curve for
patients with pathological complete response (ypCR) and other stages
(others) of disease
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gical resection alone without prior treatment there was a
linear relationship between the chance of nodal metastasis
and pT stage, this clear association was lost in those who
had had chemoradiation.7 Response in the primary tumor
does not necessarily imply equal response in the lymph
nodes. The metastatic cells may behave differently, or they
may be located outside the irradiation field.
There are difficulties assigning ypT stage in patients
who had prior treatment. The conventional TNM classifi-
cation denotes a pT stage according to the deepest layer of
the esophageal wall that is infiltrated by the tumor. After
neoadjuvant treatment, this simple gradation is lost. Often
only small clusters of residual viable cells are found in the
deep layer of the esophagus, with the superficial layers
n Median 5-year
ypN0 11 65.2 m 51%
ypN+ 64 21 m 18.4%
n Median 5-year
ypV0 55 124.8m 61.6%
ypV+ 56 24.6m 37.3%
n Median 5-year
ypV0 23 21.1m 27.4%
ypV+ 41 17.4m 12.5%
n Median 5-year
ypT0 77 86.8 m 51.9%
ypT1 18 46.5 m 39.7%
ypT2 36 38.7 m 43.8%
ypT3 39 18.2 m 0%
ypT4 5 7.1 m 0%
n Median 5-year
ypV0 78 86.8 m 51.9%
ypV1 42 46.5 m 41.4%
ypV2 18 27.5 m 23.6%
ypV3 37 14.2 m 17.5%
1.0
0.8
0.6
0.4
0.2
Survival
b
p < 0.01
a
1.0
0.8
0.6
0.4
0.2
1600 140
Months
100 12060 804020
Survival
p = 0.006
e
1.0
0.8
0.6
0.4
0.2
Survival
1.0
0.8
0.6
0.4
0.2
Survival
c
p = 0.043
1.0
0.8
0.6
0.4
0.2
Survival
d
p = 0.368
1600 140
Months
100 12060 804020
1600 140
Months
100 12060 8040201600 140
Months
100 12060 804020
1600 140
Months
100 12060 804020
FIG. 2 a Survival curve
dependent on ypT stage disease. b
Survival curve for patients with
(ypN?) or without (ypN0) nodal
metastases. c Survival curve of
ypV0 (without residual malignant
cells in primary tumor) versus
ypV? (with residual malignant
cells) in patients with ypN0. d
Survival curve of ypV0 (without
residual malignant cell in primary
tumor) versus ypV? (with
residual malignant cell) in
patients with ypN?. e Survival
curve of patient in relation to the
amount of viable cell categorized
according to the Guidelines of
Japanese Society for Esophageal
Disease
TABLE 2 Multivariate analysis on factors predictive of survival of
patients treated with neoadjuvant chemoradiation and surgery
HR 95% CI P value
Gender
Male 3.011 1.381–6.567 .006
Female (reference) 1
ypN stage
ypN0 (reference) 1
ypN1 1.713 1.118–2.625 .013
ypV stage 1.362 1.151–1.612 \.001
HR hazard ratio, CI confidence interval
Reference against which hazard rations are calculated
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sterilized. It is not clear if assigning a ypT stage according
to this layer is appropriate. Instead, looking at the percent
of residual viable tumor may be a better way to measure
the severity of disease status.
Different grading systems have been reported to assess
the degree of primary tumor response after neoadjuvant
therapy (Table 4). Mandard and associates first reported
the importance of taking into account the degree of tumor
regression as an important survival prognostic factor.28 The
grading system was based on the amount of residual viable
cells and posttherapeutic fibrosis. Schneider divided the
percent of viable cells into 0%, \10%, 10%–50%,
and [50%.11 Chirieac used slightly different dividing
points as 0%, 1%–50%, and [50%.8 The Japanese Society
for Esophageal Disease published a guideline to assess the
degree of primary tumor response by dividing the propor-
tions of viable cell into thirds.16 From our data, it seems
certain that ypV is of prognostic significance both as a
continuous or a categorical variable (Tables 2 and 3). For
the ease of daily clinical application, the ability to divide
ypV into discrete grades could be useful. A clear trend is
seen in survival from ypV0 to ypV3 (Fig. 2e). However,
the choice of different categories is arbitrary. Consistently
reproducible categories are not yet available in the litera-
ture. This may in part be related to different ways of
assessing histological regression. One potential limitation
on assessing the percent of viable cells is that spontaneous
tumor necrosis can occur in any tumor, particularly if the
necrosis is confined to the center of a large tumor cell
clump, and this may not be related to treatment effect.
Distinction between the two mechanisms is not possible by
histological examination. A scar area is presumed to have
developed after tumor necrosis. However, scarring might
occur without prior tumor’s presence.
Undoubtedly, nodal status is an important prognostic
factor. The ypN stage is shown in the present study as an
important factor. Gaca et al. demonstrated in 101 patients
who had chemoradiation that the ypN status was the only
TABLE 3 Multivariate analysis on factors predictive of survival
with residual viable cell as categorical variable
HR 95% CI P value
Gender
Male 3.042 1.390–6.567 .005
Female (reference) 1
ypN stage
ypN0 (reference) 1
ypN1 1.712 1.117–2.624 .014
ypV stage .005
ypV0 (reference) 1
ypV1 1.561 0.912–2.672 .105
ypV2 1.829 0.894–3.739 .098
ypV3 2.592 1.530–4.386 \.001
HR hazard ratio, CI confidence interval
Reference against which hazard rations are calculated
V0: No residual viable malignant cell in primary tumor. V1: 1%–33%
of residual malignant cell remaining in primary tumor. V2: 34%–66%
of residual malignant cell remaining in primary tumor. V3: 67%–
100% of residual malignant cell remaining in primary tumor
TABLE 4 Currently available
grading systems for evaluation
of the primary tumor response
after chemoradiation therapy
Authors Tumor
grading
Features of primary tumor
Chirieac LR et al. 20058 1 0% of residual cell
2 1%–50% of residual viable cell
3 [50% of residual viable cell in primary tumor
Schneider PM et al.11 1 [50% vital residual tumor cells (VTRCs)
2 10%–50% VTRCs
3 \10% VTRCs
4 0 VTRCs
Japanese Society
of Esophageal Disease16
0 Ineffective
1 Slightly effective: Viable cell more than 1/3 of tumor
tissue, but with evidence of degeneration
2 Moderately effective: Viable cell less than 1/3 of tumor
tissue and severely degenerated or necrotic
3 Markedly effective: No viable cell
Mandard AM et al. 199428 1 Complete response ? fibrosis
2 Scattered viable cells ? fibrosis
3 Increased number of viable cell but fibrosis still
predominated
4 Amount of residual cells outgrowing fibrosis
5 Absence of regressive change
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prognostic factor for disease-free survival.29 Similar find-
ings were reported by Reynolds et al.27 It is important to
note that in our patients who had ypN0 disease, ypV0
patients survived longer than those who had ypV? disease.
This difference was not significant in patients who had
nodal metastases (ypN?). This is not unexpected as the
importance of metastatic disease overrides the status of the
primary tumor.
In summary, we have shown that the pretherapeutic
clinical TNM stage has no prognostic value in patients who
had neoadjuvant chemoradiation. Gender, nodal status, and
the percent of residual viable cells in the primary tumor
were independent prognostic factors. ypV assessment
should replace conventional ypT stage as a prognostic
factor.
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